New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22315258.
- Also identified by DOI 10.1378/chest.11-2294 and PMC identifier 3278067.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical testing. Development of these new agents was prompted by the limitations of existing antiplatelet, anticoagulant, or fibrinolytic drugs. Addressing these unmet needs, this article (1) outlines the rationale for development of new antithrombotic agents; (2) describes the new antiplatelet, anticoagulant, and fibrinolytic drugs; and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.
Medical subject headings
- Drugs, Investigational
- Evidence-Based Medicine
- Fibrinolytic Agents
- Practice Guidelines as Topic
- Societies, Medical
- Thrombosis